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The performance of a sandwich enzyme-linked immunosorbent assay (ELISA) which detects Aspergillus 
galactomannan (GM) was evaluated in bronchoalveolar lavage (BAL) fluid samples from 19 patients who were 
treated for hematological malignancies and who were suspected of having invasive pulmonary aspergillosis 
(IPA), All patients had fever and pulmonary infiltrates on the chest roentgenogram on the day that the BAL 
fluid was obtained. The ELISA results were compared with the results of culture and Aspergillus genus-specific 
PCR analysis of BAL fluid samples. ELISA was also performed with serum samples. Aspergillus species were 
detected by PCR or ELISA with BAL fluid samples from five of seven patients who had radiological evidence 
of IPA. Serum ELISA results were positive for all patients with ELISA-positive BAL fluid, and for four patients 
the serum ELISA was positive before the BAL fluid was obtained. PCR and ELISA were positive for 2 and I 
of 10 BAL fluid samples, respectively, obtained from patients without radiological evidence of IPA, and 5 and
2 of 35 BAL fluid samples, respectively, obtained from nonneutropenic patients. This preliminary investigation 
suggests that GM may be detected by ELISA in BAL fluid samples from patients at risk of IPA, but that 
monitoring of serum GM levels may allow for the earlier diagnosis of IPA. However, further evaluation in 
prospective studies is required.
Invasive pulmonary aspergillosis (IPA) is a major threat to 
leukemic patients with cytotoxic therapy-induced neutropenia 
and transplant recipients receiving high-dose corticosteroid 
therapy. Since the diagnosis of IPA in an early stage is seldom 
possible and the mortality rate is very high (6), successful 
treatment is directly related to early diagnosis (1), Several 
methods for obtaining an early and rapid diagnosis of IPA are 
now under study. Aspergillus DNA can be detected in bron­
choalveolar lavage (BAL) fluid by PCR (5,16, 18, 22, 25), but 
the numbers of patients and controls tested have been too 
limited to establish the diagnostic value of this technique. An 
alternative approach is to detect circulating Aspergillus antigen 
in body fluids, e.g., serum or urine, by a number of in-house 
methods (12, 19, 20). The Aspergillus antigen test (Pastorex 
Aspergillus  ^ Sanofì Diagnostics Pasteur, Marnes-la-Coquette, 
France) is commercially available and uses the rat monoclonal 
antibody EB-A2 to detect galactomannan (GM), a polysaccha­
ride antigen of Aspergillus species (13). This antigen test has 
been evaluated in several institutes (4, 8, 9, 26, 29), but it has 
been found to lack sufficient sensitivity (8, 9, 26, 29). A recent­
ly developed sandwich enzyme-linked immunosorbent assay 
(ELISA) allowed the detection of low levels of circulating 
Aspergillus GM in sera from patients at high risk of IPA, but 
the increase in sensitivity was also associated with false-positive 
results in up to 8% of the serum samples (21, 27). Since IPA is
predominantly a pulmonary infection in immunocompromised 
patients, and Aspergillus fumiga tus is known to release GM into 
the culture medium when it is grown in vitro (13), detectable 
antigen levels may be present in BAL fluid samples from pa­
tients suspected of having IPA and therefore may be of use for 
the diagnosis of' IPA.
We therefore investigated the use of the sandwich ELISA to 
detect GM with BAL fluid samples which had been collected 
from patients at high risk and from patients at low risk of IPA, 
The results were compared with those obtained by culture and 
Aspergillus genus-specific PCR amplification and were related 
to the clinical outcome.
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MATERIALS AND METHODS
Patients. During a '12-month period 19 consecutive BAL fluid samples had 
been collected from patients who were neutropenic as a result of cytotoxic 
therapy or from whom circulating granulocytes were recovered. In each patient 
a bronchoscopy was performed because fever (temperature, >38.3°C) persisted 
despite treatment with broad-spectrum antibacterial agents and pulmonary in­
filtrates developed on the chest roentgenogram. The BAL Huid sample was 
obtained by wedging a flexible bronchoscope in the area of maximal roeutgen- 
ographic involvement, after which 150 ml of sterile 0.9% saline was instilled and 
approximately 100 ml was recovered by suclioning. The medical, histopalholog- 
ical, microbiological, and radiological records of all patients were reviewed for 
evidence of IPA or other respiratory disease. Since a definitive diagnosis of IPA 
is very difficult to establish in this patient group, the patients were allocated to 
three categories by review of the appearance oí the pulmonary infiltrates on the 
chest roentgenogram by two physicians who were blinded to the medical histories 
of the patients. The patients were allocated to one of the following groups: A, 
probable IPA (n = 7), with the chest roentgenogram showing focal nonanatomi- 
cal infiltrates or any cavitating lesion; C> unlikely IPA (n -  10), with the chest 
roentgenogram showing diffuse infiltrates characterized by nodular, reticular, or 
reticulonodular lesions which were distributed throughout both lung fields or 
anatomical focal infiltrates (15); and B, possible IPA (n = 2), which included
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patients with infiltrates on the chest roentgenogram who could not be classified 
intu group A  or C. Of course, the reliability of these definitions is limited because 
the roentgenographic pattern is not always specific for the infectious etiology of 
the infiltrates. Furthermore, 35 BAL Huid samples were collected 1’rom nonneu- 
tropenic patients who were at low risk for IPA.
Sample collection. BAL fluid samples were routinely examined for the pres­
ence of bacteria, viruses, fungi, and parasites, A total of 5 to 1(1 ml of each sample 
was stored at —8U°C until analysis by ELISA and PCR. The microbiological 
records were reviewed for serum samples winch had been collected from each 
patient between 6 weeks before and 2 weeks after the BAL Huid sample was 
obtained. These samples had also been stored at —80°C until testing by ELISA 
was performed.
Aspergillus culture. Routine culture for fungi was performed after centrifuga­
tion of the BAL fluid sample at 1,500 x  g for 10 min. The pellet was plated onto 
Sabouraud glucose (2%)  agar and was cultured for 5 days at 28 and 48ÜC. 
Aspergillus species were identified by one technician (AJ.M.VLR.) by their cul­
tural characteristics and the morphologies of their conidiophores and conidia.
PCR amplification. After thawing, the BAL fluid samples were centrifuged at 
1,500 X g  for 1(1 min. The supernatant was separated from the pellet, leaving a 
residue of 0.5 ml in which the pellet was resuspended. PCR analysis was per­
formed as described previously (16, 25). Briefly, high-frequency shaking was 
performed to achieve complete cell destruction; this was followed by purification 
of nucleic acids by guanidium thiocyanate-containing lysis buffer and silica par­
ticles. A hot-start PCR was performed with two Aspergillus genus-specific prim­
ers. This PCR assay can detect a wide range of the Aspergillus species involved in 
human disease specifically when it is combined with Southern blot hybridization 
and restriction enzyme analysis (16).
ELISA. The sandwich ELISA used to delect Aspcjgillw  GM in serum samples 
and BAL fluid supernatants was performed exactly as described previously (21). 
Saline (0.9%) and culture- and PCR-negative BAL fluid supernatants from 
patients at low risk of IPA containing a range of dilutions of GM (range, 0.25 to
10 ng/ml) and a negative control BAL fluid sample were included in each test. All 
serum and BAL fluid samples were tested in duplicate by one technician who was 
unaware of the clinical data. The microtiter plates were prepared by the manu­
facturer (Sanofi Pasteur Diagnostics), and the coating conditions of the plates 
are proprietary. However, since the coating conditions of the EB-A2 monoclonal 
antibody on the microtiter plate were different from those reported previously 
(21), lower optical density values were found.
TABLE L Results oi Aspergillus genus-specific PCR amplification 
and sandwich ELISA of BAL fluid samples obtained from 
19 patients with hematological malignancies and
35 nonneutropenic patients
RESULTS
Aspergillus ELISA. Different concentrations of GM (range,
0.25 to 10 ng/ml) were added to 0.9% saline and culture- and 
PCR-negative BAL fluid samples from low-risk patients and 
were analyzed by ELISA. The degree of increase in the optical 
density values of 0.9% saline spiked with increasing concen­
trations of GM was directly proportional to that found with 
culture- and PCR-negative BAL fluid samples spiked with the 
sama concentrations of GM (data not shown). The mean op­
tical density values of the 30 BAL fluid samples from nonneu­
tropenic patients with negative fungal culture and PCR results 
were used to study the ELISA background. There was a Gaus­
sian distribution of the optical density values, allowing a cutoff 
value of 0.17 to be calculated from the mean optical density 
value (mean optical density value, 0.09; range, 0.056 to 0.146) 
plus 4 standard deviations. The optical density of control se­
rum spiked with 1 ng of GM per ml was used as cutoff value for 
serum (optical density value, 0.17) (21). The results of Aspergil­
lus genus-specific PCR and ELISA for the BAL fluid samples 
from 19 patients with hematological malignancies and the BAL 
fluid samples from 35 control patients are given in Table 1.
Clinical data. The characteristics of the 19 patients with 
hematological malignancies and the results of culture, PCR, 
and ELISA are given in Table 2. Five of seven BAL fluid 
samples from patients with probable IPA were positive by PCR 
and ELISA. GM was detected in serum samples from all pa­
tients with an ELISA-posilive BAL fluid sample. Moreover, 
serum samples were available from the period before the bron­
choscopy was performed for four patients, and GM could be 
detected up to 30 days before the BAL fluid sample was ob­
tained (patient A5; Table 2). Shortly after bone marrow trans­
plantation during severe neutropenia, patient A5 developed 
fever and sinusitis. The administration of ciprofloxacin and
Microbiological 
analysis result
No. of patients
Hematologic
patients
Nonneutropenic
patients
PCR positive, ELISA positive 5 0
PCR positive, ELISA negative 3 5
PCR negative, ELISA positive 2 2
PCR negative, ELISA negative 9 28
Total 19 35
amoxicillin-clavulanic acid did not result in clinical improve­
ment, and amphotericin B (1 mg/kg of body weight per day) 
was added to the regimen. During recovery of the granulo­
cytes, a chest roentgenogram showed the development of a 
nodular infiltrate. Although culture of sinus aspirate and BAL 
fluid remained negative, PCR and ELISA of BAL fluid sam­
ples were positive, and GM was retrospectively detected in the 
serum at the time that the sinusitis first became apparent.
Both PCR and ELISA were positive for one o f two BAL 
fluid samples from patients with possible IPA, but serum sam­
ples were not available for analysis by the ELISA. The PCR 
was positive for BAL fluid samples from patients C l and C2, 
who had no evidence of the presence of IPA, and GM was not 
detected in the BAL fluid or serum samples from these pa­
tients. GM was detected in a PCR-negative BAL fluid sample 
from patient C3, and two of seven serum samples were also 
found to be positive. The two ELISA-positive serum samples 
were obtained on the day that the BAL was performed and 1 
day thereafter, respectively. Five consecutive serum samples 
obtained during 2 weeks following the BAL were all negative, 
even though severe neutropenia persisted and at the time of 
the seroconversion only a loading dose of 10 mg of amphoter­
icin B had been administered. Treatment with ciprofloxacin 
and amphotericin B (1 mg/kg/d ay) for 2 weeks resulted in 
resolution of the pulmonary infiltrates.
Nonneutropenic patients. PCR analysis of 35 BAL fluid 
samples from nonneutropenic patients revealed positive am­
plification reactions for five samples which were all negative by 
ELISA (25). The ELISA was positive for 2 of 30 PCR-negative 
BAL fluid samples (Table 1).
DISCUSSION
The diagnosis of IPA  in an early stage of the disease is of 
great importance since early antifungal treatment is associated 
with an improved outcome (1). The early diagnosis of IPA is 
difficult, and a definitive diagnosis is often made at autopsy. 
The presence of severe thrombocytopenia in neutropenic pa­
tients limits the use of invasive diagnostic procedures to obtain 
a specimen for culture and histopathological examination. 
BAL has been advocated as a safe procedure for obtaining a 
specimen for the diagnosis of IPA in immunocompromised 
patients with pulmonary infiltrates. Although the recovery of 
Aspergillus species from BAL fluid is highly indicative of IPA, 
the diagnostic yield from culture of BAL fluid samples is only 
30% (24). Therefore, attention has focused on other tech­
niques for the early diagnosis of IPA, such as Aspergillus - 
specific PCR of BAL fluid (5, 16, 18, 22) and the detection of 
circulating Aspergillus antigen in serum or urine (4, 8, 9, 12, 
19-21, 26, 29). Little is known about the utility of Aspergillus 
antigen detection in BAL fluid. One research group has pre­
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TABLE 2. Characteristics of 19 patients with hematological malignancies and results of analysis of BAL fluid samples by
culture and Aspergillus genus-specific PCR and BAL fluid and serum samples by ELISA
Patient Sex/' age 
no. (yr)
Underlying 
disease and/ 
or condi­
tio n(s)c'
BAL Huid analysis
Culture PCR ELISA'
No. of samples 
positive by se­
rum ELÌSA/ 
total no. of 
samples
Time between 
first positive 
serum and
BAU'
Granulocyte
count
(10‘Vliter)
Outcome
A 1 M, 43 NHL Aspergillus fum igatus 0,581 (+) 3/3 - 4 3.6 Deceased
2 M, 36 NHL Aspergili us fum igatus + 0.278 (+) 3/4
-t 5,8 Deceased
3 M, 48 HL Aspergillus fumigatus + 0.128 ( - ) 0/3 2.5 Survived
4 M, 54 AML Stenotroph omot ï as n with o - + 1.322 (+) 1/1 <0.1 Survived
ph i lia
5 M, 22 AA, BMT Citrobacter freiindii, Kleb­ 0.370 (+) 25/28 - 3 0 <0.1 Survived
siella pneumoniae
6 M, 58 MDS, BMT Negative — 0.247 (+) 3/11 -11 2.1 Survived
7 M, 20 Myelofibrosis Pscitdomonas aeruginosa, 0.095 ( - ) NA'' <0.1 Deceased
Candida albicans
B 1 M* 59 AML Negative + 0.736 (+) NA <0.1 Survived
2 M, 68 NHL Candida gl abra ta — 0.113 ( - ) NA 9.2 Deceased
C 1 M, 48 AML, BMT Candida glabrata 0.152 ( - ) 0/1 <0.1 Survived
2 F, 36 AML Negative + 0.122 ( - ) NA <0.1 Deceased
3 M, 34 CML, BMT Cat id ida già bra ta — 0.220 (+) 2/7 <0.1 Survived
4 F, 52 MM Negative — 0.093 ( - ) 0/1 <0.1 Deceased
5 F, 43 ALL, BMT Candida albicans — 0.075 ( - ) 0/5 3.8 Deceased
6 F, 40 AML Negative — 0.077 ( - ) 0/1 2.1 Survived
7 F, 44 MM Herpes simplex virus — 0.087 ( - ) 0/1 3.5 Survived
8 F, 62 CLL Pneumocystis carinifi — 0,079 ( - ) NA 2.0 Deceased
9 F, 56 AML Candida albicans 0.114 (-0 0/2 <0.1 Deceased
10 F, 72 AML Negative — 0.098 ( - ) 0/2 <0.1 Deceased
u Categories: A, probable IPA, with the chest roentgenogram showing focal nonanatomical infiltrates or any cavitating lesion; B, possible IPA in patients with 
infiltrates on the chest roentgenogram who could not be classified into group A or C; C, IPA unlikely, with the ehest roentgenogram showing diffuse infiltrates 
characterized by nodular, reticular, or reticulonodular lesions which were distributed throughout both lung fields or anatomical focal lesions. 
h M, male; F, female.
c NHL, non-Hodgkin’s lymphoma; HL, Hodgkin's lymphoma; AML, acute myeloid leukemia; AA, aplastic anemia; BMT, bone marrow transplantation; MDS, 
myelodysplastic syndrome; CML, chronic myeloid leukemia; MM, multiple myeloma; CLL, chronic lymphoblastic leukemia.
11 Patients from whom at least one serum sample was taken within 6 weeks before the BAL fluid sample was obtained. Values are numbers of days between the time 
the first serum sample was found to be positive by ELISA and the date of bronchoscopy. 
c Optical density value; plus and minus signs indicate interpretation of results.
^NA, not available.
s Microscopic detection with Giemsa staining.
viously described the use of a radioimmunoassay to detect an 
uncharacterized purified A. fumigatus carbohydrate in BAL 
fluid (2, 3, 30). This radioimmunoassay detected Aspergillus 
antigen in 91% of the BAL fluid samples from rabbits with 
IPA, and in 21% of these animals antigen was detected in BAL 
fluid only and not in serum (2). The radioimmunoassay was 
also used to detect Aspergillus antigen in BAL fluid samples 
from nine immunocompromised patients with pulmonary in­
filtrates, and two patients were found to be positive (3). GM 
was detected by a latex agglutination test (Pastortx Aspergillus) 
in BAL fluid samples from three patients with AIDS and IPA
(14). However, GM could not be detected by the same test 
under laboratory conditions in BAL fluid samples from 14 
untreated rabbits with IPA, while serum samples from 10 
(71%) animals were positive (7). Although the present study 
was limited by the difficulty in reliably classifying patients with 
IPA, GM was detected by sandwich ELISA in BAL fluid sam­
ples from five of seven patients with radiological evidence of 
IPA, and therefore, this test may be promising for use in the 
diagnosis of this infection.
The increase in the level of sensitivity required to diagnose 
early IPA, however, is hampered by an increase in the number 
of false-positive results. For this reason, it was interesting to 
compare DNA and GM detection, since these two assays have 
a different target. In the case of diagnosis by PCR, a positive
result obtained from the use of a BAL fluid sample can be due 
to the presence of contaminating conidia without any mycelial 
development (see, for example, data for patients Cl and C2). 
Indeed, previous studies found a rate of 15% positive PCR 
amplification in BAL fluid samples from nonneutropenic pa­
tients (22, 25). The occurrence of a negative PCR result for 
patient A6, whose BAL fluid and serum samples were GM 
positive and who had radiological and clinical evidence of IPA, 
could be due to the presence of inhibitors of the PCR in the 
BAL fluid (23).
False-positive results were also obtained by the sandwich 
ELISA. The reasons for the false-positive reactions are un­
known, but it has been shown that molecules which are respon­
sible for the false positivity appear to mimic the epitope rec­
ognized by anti-GM monoclonal antibodies (2 1 ). In 30 culture- 
and PCR-negative BAL fluid' samples from nonneutropenic 
patients, a 7% false-positive rate was found, which is similar to 
the 8% false-positive rate found in serum (21). A 10-fold con­
centration of the samples by acetone precipitation resulted in 
a false-positive rate of 27% (data not shown). Analysis by PCR 
and ELISA can be done in less than 24 h (PCR, 24 h; ELISA,
4 h), and the results can be forwarded to the clinician on the 
day following the BAL.
An excellent correlation was found between serum and BAL 
fluid ELISA results, and GM was detected in the serum even
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before the BAL was performed. Since a bronchoscopy was 
performed only after pulmonary infiltrates were present on the 
chest roentgenogram, GM may be detectable in the serum 
before infiltrates become visible on the plain chest film. It has 
been shown that in neutropenic patients abnormalities are 
difficult to detect on plain chest film (17) and that other radio­
logic methods, such as high-resolution computed tomography, 
are more sensitive for the detection of pulmonary infiltrates in 
these patients (1.0, 1 1 , 28) and may even be used for therapeu­
tic monitoring (28).
This preliminary investigation suggests that both Aspergillus 
genus-specific PCR and sandwich ELISA might be beneficial 
for use in the early diagnosis of IPA in patients with hemato­
logical malignancies. The ELISA is relatively easy to perform, 
and the results are available within 4 h. Since false-positive 
results may be found by ELISA of the serum, detection of 
Aspergillus species in BAL fluid by ELISA or PCR may provide 
additional evidence for the presence of IPA. The results of the 
present study also suggest that in some patients GM antigen- 
emia may be detected in serum before pulmonary infiltrates 
are visible on the chest roentgenogram. However, carefully 
designed prospective studies need to be performed in order to 
evaluate the diagnostic value of these assays. We are prospec- 
lively monitoring serum GM levels by ELISA in patients dur­
ing cytotoxic therapy-induced neutropenia. When GM is de­
tected for the first time, confirmation is sought by ELISA with 
additional serum samples, high-resolution computed tomogra­
phy scan, and where possible, bronchoscopy and PCR analysis 
of BAL fluid. Once the presence of GM is confirmed or the 
signs or symptoms pathognomonic for IPA have developed, 
treatment with antifungal agents is started preemptively. By 
following these guidelines, the diagnosis and treatment of IPA 
may be possible at an early stage of infection.
REFERENCES
1. A isner,J . ,  S. C. SchimpfF, and P. H. Wiernik, 1977. Treatment of invasive 
aspergillosis; relation of early diagnosis and treatment to response. Ann. 
Intern. Med. 86:539-543.
2. Andrews, C. P., and ML II. Werner, 1981. Immunodiagnosis of invasive 
pulmonary aspergillosis in rabbits. Fungal antigen detected by radioimmu­
noassay in bronchoalveolar lavage fluid. Am. Rev. Respir, Dis. 124:60-64.
3. Andrews, C. P., and M. II, Werner. 1982. Aspergi Hits antigen detection in 
bronchoalveolar lavage fluid from patients with invasive aspergillosis and 
aspcfgillomas. Am. J. Med. 73:372-380.
4. Ansorg, R., E. Heintschel von Heinegg, and P, Mt Rath. 1994. Aspergillus 
antigenuria compared to an tige ne mia in bone marrow transplant recipients. 
Eur. J. Clin. Microbiol. Infect. Dis. 13:582-589,
5. Bretagne, S., J. M. Costa, A. Marmorat-Khuong, F. Poron, C. Cordonnier, 
M. Vidaud, and J. FIcury-Fcith. 1995. Detection of Aspergillus species DNA 
in bronchoalveolar lavage samples by competitive PCR. J. Clin. Microbiol. 
33:1164-1168.
6. Bodey, G., 13. Buclínuinn, W. Dugtiid, D. Gibbs, H. Hanak, M. Hotchi, G. 
Mall, P. Martino, F. Meunier, S. Milliken, S. Naoe, M. Ohidaira, D. Seevola, 
and J. van’t Wout, 1992. Fungal infections in cancer patients: an interna­
tional autopsy survey. Hur. J. Clin. Microbiol, Infect. Dis. 11:99-109.
7. Francis, P., J. W. Lee, A. Hoffman, J. Peter, A. Francesconi, J. Bacher, J. 
Shelhainer, P. A. Pizzo, and T. J. Walsh. 1994. Elììcacy of unilamellar 
liposomal amphotericin B in treatment of pulmonary aspergillosis in persis­
tently granulocytopenic rabbits: the potential role of bronchoalveolar d -  
manm'to! and serum galactomannan as markers of infection. J. Infect. Dis. 
169:356-368.
K. Ilaynes, K., and T. R. Rogers. 1994. Retrospective evaluation of a latex 
agglutination test for diagnosis of invasive aspergillosis in immunocompro­
mised patients. Eur. J. Clin. Microbiol. Infect, Dis. 13:670-674.
9. llopwood, V., E. M. Johnson, J. M. Cornish, A. B. M. Foot, E. G. V. Evans, 
and D. W. Warnock. 1995. Use of the Pastorex aspergillus antigen latex 
agglutination test for the diagnosis of invasive aspergillosis. J. Clin. Pathol, 
48:210-213.
10. Kuhlman, J. E., E. K. Fishman, P. A. Burch, J. E. Karp, E. A. Zerhouni, and
S. S. Siegelman. 1987. Invasive pulmonary aspergillosis in acute leukemia: 
the contribution of CT to early diagnosis and aggressive management. Chest 
92:95-99.
11. Kuhlman, J. E., E. K, Fishman, and S. S. Siegelman. 1985, Invasive pulmo­
nary aspergillosis in acute leukemia: characteristic findings on CT, the CT 
halo sign, and the role of CT in early diagnosis. Radiology 157:611-614,
12. Kurup, V. P., and A. Kumar. 1991. Immunodiagnosis of aspergillosis. Clin. 
Microbiol. Rev. 4:439-456.
13. Latgé, J. P., H. Kobayashi, J. P. Debeaupuis, M. Diaqtiin, J .  Sarfati, J. M. 
Wieruszeski, E. Parra, J, P. Bouchara, and B. F o u rn e t  1994. Chemical and 
immunological characterization of the extracellular galactomannan of A s­
pergillus fumigatus. Infect, Immun. 53:5424-5433.
14. Lorlholary, O., M. C. Meyohas, B. Dupont, J, Cadranel, D. Salmon-Ceron, 
D. Peyramond, and D. Simonin. 1993. Invasive aspergillosis in patients with 
acquired immunodeficiency syndrome. Am. J. Med. 95:177-187.
15. Maile, C. W., A. V. Moore, S. Ulreich, and C. E. Putman. 1983. Chest 
radiographic-pathologic correlation in adult leukemia patients. Invest. Ra­
diol. 18:495-499.
16. Melchers, W. J. G., P. E. Venveij, P. Van Den Hurk, A. Van Belkum, B. E. De 
Pauw, J. A. A. Hoogkamp-Korstanje, and J. F. G. M. Meis. 1994, General 
primer-mediated PCR for detection o f Aspergillus species. J. Clin. Microbiol. 
32:1710-1717.
17. Pasmans, H. L., O, J. Loosveld, H. C. Schouten, F. Thunnisscn, and J. M. 
Van Engelshoven. 1992, Invasive aspergillosis in immunocompromised pa­
tients: findings on plain film and (HR) CT. Eur. J. Radiol, 14:37-40.
18. Reddy, L. V„ A. Kumar, and V. P. Kurup. 1993. Specific amplification of 
Aspergillus fumigatus DNA by polymerase chain reaction. Mol. Cell. Probes 
7:121-126.
19. Rogers, T. R., K. A. Haynes, and R. A. Barnes. 1990. Value of antigen 
detection in predicting invasive pulmonary aspergillosis. Lancet 336:1210- 
1213.
20. Sabetta, J. R., P. Miniter, and V. T» Andriole, 1985. The diagnosis of invasive 
aspergillosis by an enzyme-linked immunosorbent assay for circulating anti­
gen. J. Infect. Dis. 152:946-953.
21. Stynen, D,, A. Goris, J. Sarfati, and J. P. Latgé. 1995. A new sensitive 
sandwich ELISA to detect galactofuran in patients with invasive aspergillo­
sis. J. Clin. Microbiol. 33:497-500.
22. Tang, C, M,, D. W. Holden, A. Aufauvre-Brown, and J. Cohen. 1993. The 
detection oí Aspergillus spp. by the polymerase chain reaction and its eval­
uation in bronchoalveolar lavage fluid. Am. Rev. Respir, Dis. 148:1313—1317.
23. Tjhie, J. H., F. J. M. Van Kuppeveld, R. Roosendaal, W. J. G, Melchers, R. 
Gordijn, D. M. MacLaren, J. M. M. Walboonicrs, C. J. L. M. Meijer, and 
A. J. C. Van den Brule. 1994. Direct PCR enables detection of Mycoplasma 
pneumoniae in patients with respiratory tract infections. J. Clin. Microbiol, 
32:11-16.
24. Venveij, P. E., B. E. De Pauw, D. Ruiter, J. A. A. Hoogkamp-Korstanje, and
J. F. G. M. Meis. 1994. Eight-year survey of autopsy cases with invasive 
aspergillosis in a tertiary care hospital, abstr. MS-7/12, p, 359, ht Program 
and abstracts of the 7th International Congress of the International Union of 
Microbiological Societies, Division of Mycology. International Union of Mi­
crobiological Societies, Prague.
25. Venveij, P. E., J. F. G. M. Meis, P. Van Den Hurk, B. E. De Pauw, J. A. A. 
Hoogkamp-Korstanje, and W, J. G. Melchers. 1994. Polymerase chain reac­
tion as a diagnostic tool for invasive aspergillosis: evaluation in bronchoal­
veolar lavage fluid from low risk patients. Serodiagn. Immunother. Infect. 
Dis, 6:203-208.
26. Venveij, P. E., A. J. M. M. Rtfs, B. E. De Pauw, A. M. Horrevorts, J. A. A. 
Hoogkamp-Korstanje, and J. G. F. M. Meis. 1995. Clinical evaluation and 
reproducibility of the Pastorex Aspergilhis antigen latex agglutination test for 
diagnosing invasive aspergillosis, J. Clin, Pathol. 48:474-476.
27. Venveij, P. E., D. Stynen, A. J. M. M. Rijs, B. E. De Pauw, J. A. A. 
Hoogkamp-Korstanje, and J. F. G, M. Meis. 1995. Sandwich enzyme-imnui- 
noassay compared with Pastorex latex agglutination test for diagnosing in­
vasive aspergillosis in immunocompromised patients, J. Clin, Microbiol. 33: 
1912-1914.
28. Walsh, T. .J., K. Garrett, E. Feuerstein, M. Girton, M. Allende, J. Bacher, A. 
Franeesconi, R. Schaufele, and P. A. Pizzo. 1995. Therapeutic monitoring of 
experimental invasive pulmonary aspergillosis by til tra fast computerized to­
mography, a novel, noninvasive method for measuring responses to antifun­
gal therapy. Antimicrob. Agents Chemother. 39:1065-1069.
29. Warnock, D. W., A. B. M. Foot, E. M. Johnson, S. B. Mitchell, J, M. Cornish, 
and A. Oakhill. 1991, Aspergillus antigen latex test for diagnosis of invasive 
aspergillosis. Lancet 338:1023-1024.
30. Werner, M. H., G. II. Talbot, S. L. Gerson, R. Fetchick, C. Andrews, j .  E. 
Peacock, G. Filice, M. Cohen, M. Provencher, and I’. Cassileth, 1986. De­
tection of fungal antigen in body fluids for diagnosis of invasive aspergillosis, 
Zentralbl. Bakteriol. Mikrobiol. Hyg. A 261:517-522.
